Investing in biotech stocks can be a lucrative opportunity as the biotech sector is a hub for innovation. Artificial intelligence (AI) has also turbocharged the industry, creating new opportunities in drug discovery and treatment.
Clinical-stage or development-stage biotech stocks, in particular, can offer substantial rewards, but they also come with significant risks. These companies focus on developing drugs or therapies that are still undergoing clinical trials or are awaiting regulatory approval.
